Sign in to edit your profile (add interests, mentoring, photo, etc.)

    David Feifel

    TitleProfessor In Residence
    SchoolUniversity of California, San Diego
    DepartmentPsychiatry
    Address9500 Gilman Drive #0957
    CA La Jolla 92093
    Phone619-543-8747
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview

      Biography

      Dr. David Feifel earned a Bachelors of Science, Master’s Degree and a Ph.D.(neurobiology) from the University of Toronto, Canada, where he also earned a Medical Degree. After completing an internship in Internal Medicine at the Toronto General Hospital, Dr. Feifel completed his residency training in Psychiatry at the University of California, San Diego, where he served as Chief Resident for the UCSD Outpatient Psychiatry Services in 1994. In 1995 he joined the faculty of the Department of Psychiatry in which he currently holds the rank of full Professor. He is also a faculty member in the UCSD Neurosciences Graduate Program. Dr. Feifel is the Director of the Adult Psychiatric Services at UCSD Medical Center, and the senior attending psychiatrist on the Neuropsychiatry and Behavioral Medicine Inpatient Unit (NBMU). In addition to being a Diplomate of the American Board of Psychiatry and Neurology in General Psychiatry, he is also certified in the subspecialties Psychosomatic Medicine, Behavioral Neurology and Neuropsychiatry. He has authored or co-authored numerous original scientific research papers, abstracts and book chapters.

      Research Interests

      Dr. Feifel engages in translational research related to biological treatments for mental illness. He runs a basic neuropsychopharmacology laboratory on the campus of the UCSD Medical Center. His laboratory develops animal models to explore the biological mechanisms underlying psychiatric conditions such as psychosis and to assess the potential of novel pharmacological treatments, particularly ones aimed at neuropeptide targets.

      Dr. Feifel also heads a clinical neuropharmacology research program at UCSD Medical Center. Among other things, this program evaluates the safety and efficacy of approved and investigational psychotropic medications for a large variety of psychiatric indications and, when possible, translates findings from his basic neuropharmacology research program to clinical investigations. Dr. has served as principal investigator in numerous clinical studies evaluating treatments for conditions as diverse as bipolar affective disorder, depression, schizophrenia, insomnia, as well as childhood, adolescent, and adult attention deficit / hyperactivity disorder (ADHD). His research has received funding grants from the National Association for Research in Schizophrenia and Depression (NARSAD), the Scottish Rite Organization, the Stanley Medical Research Institute and the National Institutes of Health.

      Find out more about Dr. Feifel's Research.

      Clinical Focus

      Dr. Feifel’s clinical focus is the diagnosis and treatment of psychiatric disorders stressing a biological orientation. He is Director of the Adult Psychiatric Services at UCSD Medical Center, which includes the Neuropsychiatry and Behavioral Medicine Unit (NBMU), an 18-bed inpatient unit and the Consult / Liaison service. The Psychiatry service at UCSD Medical Center, was ranked among the nations best by US News and World Report in Dr. Feifel is founder and Director of the UCSD Adult ADHD Program and the UCSD TMS Center. In addition to seeing patients, Dr. Feifel lectures and supervises medical students, residents and fellows at UCSD and he is a national lecturer on topics in psychopharmacology. Among his distinctions, Dr. Feifel is an elected member of the American College of Neuropharmacology, he has been elected by his peers for inclusion in ‘Best Doctors in America’, and he is cited in the Castle Connelly list of “Top Doctors:”

      Find more about David Feifel.


      Collapse ORNG Applications 
      Collapse Websites
      Collapse NIH Awarded Grants

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Feifel D. Breaking Sad: Unleashing the Breakthrough Potential of Ketamine's Rapid Antidepressant Effects. Drug Dev Res. 2016 Nov 26. PMID: 27888525.
        View in: PubMed
      2. Shilling PD, Feifel D. Potential of Oxytocin in the Treatment of Schizophrenia. CNS Drugs. 2016 Mar; 30(3):193-208. PMID: 26895254.
        View in: PubMed
      3. Feifel D, Shilling PD, Fazlinejad AA, Melendez G. Antipsychotic drug-like facilitation of latent inhibition by a brain-penetrating neurotensin-1 receptor agonist. J Psychopharmacol. 2016 Mar; 30(3):312-7. PMID: 26783230.
        View in: PubMed
      4. Singh F, Nunag J, Muldoon G, Cadenhead KS, Pineda JA, Feifel D. Effects of intranasal oxytocin on neural processing within a socially relevant neural circuit. Eur Neuropsychopharmacol. 2016 Mar; 26(3):626-30. PMID: 26727038.
        View in: PubMed
      5. Feifel D, Shilling PD, MacDonald K. A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia. Biol Psychiatry. 2016 Feb 1; 79(3):222-33. PMID: 26410353.
        View in: PubMed
      6. Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O'Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS. Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Brain Stimul. 2015 Jul-Aug; 8(4):787-94. PMID: 26143022.
        View in: PubMed
      7. Acheson DT, Feifel D, Kamenski M, Mckinney R, Risbrough VB. Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response. Depress Anxiety. 2015 Jun; 32(6):400-7. PMID: 25826649.
        View in: PubMed
      8. Feifel D, Shilling PD, Hillman J, Maisel M, Winfield J, Melendez G. Peripherally administered oxytocin modulates latent inhibition in a manner consistent with antipsychotic drugs. Behav Brain Res. 2015 Feb 1; 278:424-8. PMID: 25447298.
        View in: PubMed
      9. Keiser AA, Matazel KS, Esser MK, Feifel D, Prus AJ. Systemic administration of the neurotensin NTS1-receptor agonist PD149163 improves performance on a memory task in naturally deficient male Brown Norway rats. Exp Clin Psychopharmacol. 2014 Dec; 22(6):541-7. PMID: 25222546.
        View in: PubMed
      10. MacDonald K, Feifel D. Oxytocin?s role in anxiety: A critical appraisal. Brain Res. 2014 Sep 11; 1580:22-56. PMID: 24468203.
        View in: PubMed
      11. Singh F, Feifel D. Developing Research Domain Criteria (RDoC) to improve diagnosis and treatment of social deficits in psychiatric disorders: The Mirror Neuron System as a model. Schizophr Res. 2013 Dec; 151(1-3):293-4. PMID: 24094678.
        View in: PubMed
      12. Wilson MP, Macdonald K, Vilke GM, Ronquillo L, Feifel D. Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting. J Emerg Med. 2013 Dec; 45(6):901-8. PMID: 24071032.
        View in: PubMed
      13. Berquist Ii MD, Mooney-Leber SM, Feifel D, Prus AJ. Assessment of attention in male and female Brattleboro rats using a self-paced five-choice serial reaction time task. Brain Res. 2013 Nov 6; 1537:174-9. PMID: 24055104.
        View in: PubMed
      14. Macdonald K, Feifel D, Brüne M, Lamb K, Wilson MP, Golshan S, Macdonald T. Not disappointed by anxiety: A reply to Cardoso and Ellenbogen's commentary "Oxytocin and psychotherapy: Keeping context and person in mind". Psychoneuroendocrinology. 2013 Dec; 38(12):3173-5. PMID: 24035602.
        View in: PubMed
      15. Feifel D. Limited evidence that benzodiazepines are beneficial in the treatment of disturbed behaviour. Evid Based Ment Health. 2013 Nov; 16(4):111. PMID: 23956251.
        View in: PubMed
      16. Macdonald K, Macdonald TM, Brüne M, Lamb K, Wilson MP, Golshan S, Feifel D. Oxytocin and psychotherapy: A pilot study of its physiological, behavioral and subjective effects in males with depression. Psychoneuroendocrinology. 2013 Dec; 38(12):2831-43. PMID: 23810433.
        View in: PubMed
      17. Acheson D, Feifel D, de Wilde S, McKinney R, Lohr J, Risbrough V. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology (Berl). 2013 Sep; 229(1):199-208. PMID: 23644911.
        View in: PubMed
      18. Feifel D, Wilson MP, Pepper D, Currier GW, Holloman G. In reply:. West J Emerg Med. 2012 Dec; 13(6):536-7. PMID: 23875056.
        View in: PubMed
      19. Feifel D, Macdonald K, Cobb P, Minassian A. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res. 2012 Aug; 139(1-3):207-10. PMID: 22682705.
        View in: PubMed
      20. MacDonald K, Wilson M, Minassian A, Vilke GM, Becker O, Tallian K, Cobb P, Perez R, Galangue B, Feifel D. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. J Clin Psychopharmacol. 2012 Jun; 32(3):317-22. PMID: 22544013.
        View in: PubMed
      21. Arnold VK, Feifel D, Earl CQ, Yang R, Adler LA. A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. J Atten Disord. 2014 Feb; 18(2):133-44. PMID: 22617860.
        View in: PubMed
      22. MacDonald K, Feifel D. Dramatic improvement in sexual function induced by intranasal oxytocin. J Sex Med. 2012 May; 9(5):1407-10. PMID: 22458365.
        View in: PubMed
      23. Feifel D. Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacology. 2012 Jan; 37(1):304-5. PMID: 22157870.
        View in: PubMed
      24. Macdonald K, Feifel D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatr. 2012 Jun; 24(3):130-46. PMID: 22736892.
        View in: PubMed
      25. Feifel D, Shilling PD, Belcher AM. The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol. 2012 May; 22(5):374-8. PMID: 21962914.
        View in: PubMed
      26. Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, Spyker DA, Cassella JV. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 Oct; 72(10):1313-21. PMID: 21294997.
        View in: PubMed
      27. Apostol G, Abi-Saab W, Kratochvil CJ, Adler LA, Robieson WZ, Gault LM, Pritchett YL, Feifel D, Collins MA, Saltarelli MD. Efficacy and safety of the novel a4ß2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl). 2012 Feb; 219(3):715-25. PMID: 21748252.
        View in: PubMed
      28. Wilson MP, MacDonald K, Vilke GM, Feifel D. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med. 2012 Nov; 43(5):790-7. PMID: 21601409.
        View in: PubMed
      29. Feifel D, Shilling PD, Melendez G. Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats. Behav Neurosci. 2011 Apr; 125(2):268-72. PMID: 21463026.
        View in: PubMed
      30. Feifel D. Is oxytocin a promising treatment for schizophrenia? Expert Rev Neurother. 2011 Feb; 11(2):157-9. PMID: 21306203.
        View in: PubMed
      31. Feifel D, Galangue B, Macdonald K, Cobb P, Dinca A, Becker O, Cooper J, Hadley A. A Naturalistic, Single-blind Comparison of Rapid Dose Administration of Divalproex ER Versus Quetiapine in Patients with Acute Bipolar Mania. Innov Clin Neurosci. 2011 Jan; 8(1):29-35. PMID: 21311705.
        View in: PubMed
      32. Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, Spyker DA, Kehne JH, Cassella JV. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011 Jan; 198(1):51-8. PMID: 21200077.
        View in: PubMed
      33. Feifel D, Shilling PD, Melendez G. Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy. J Psychopharmacol. 2011 Jun; 25(6):836-41. PMID: 21106605.
        View in: PubMed
      34. Feifel D, Shilling PD. Promise and pitfalls of animal models of schizophrenia. Curr Psychiatry Rep. 2010 Aug; 12(4):327-34. PMID: 20544314.
        View in: PubMed
      35. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010 Oct 1; 68(7):678-80. PMID: 20615494.
        View in: PubMed
      36. MacDonald K, Wilson MP, Minassian A, Vilke GM, Perez R, Cobb P, Tallian K, Becker O, Feifel D. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients. Gen Hosp Psychiatry. 2010 Jul-Aug; 32(4):443-5. PMID: 20633750.
        View in: PubMed
      37. Wilson MP, MacDonald K, Vilke GM, Feifel D. Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients. J Emerg Med. 2012 Nov; 43(5):889-96. PMID: 20542400.
        View in: PubMed
      38. Feifel D, Pang Z, Pang Z, Shilling PD, Melendez G, Schreiber R, Button D. Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity. Behav Brain Res. 2010 Oct 15; 212(2):174-8. PMID: 20399236.
        View in: PubMed
      39. Feifel D. The Use of Placebo-Controlled Clinical Trials for the Approval of Psychiatric Drugs: Part II-Ethical Considerations Related to the Individual Participant. Psychiatry (Edgmont). 2009 Dec; 6(12):19-25. PMID: 20104288.
        View in: PubMed
      40. Feifel D, Goldenberg J, Melendez G, Shilling PD. The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacology. 2010 Jan; 58(1):195-8. PMID: 19596358.
        View in: PubMed
      41. Feifel D, Pang Z, Shilling PD, Melendez G, Schreiber R, Button D. Sensorimotor gating in neurotensin-1 receptor null mice. Neuropharmacology. 2010 Jan; 58(1):173-8. PMID: 19596359.
        View in: PubMed
      42. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009 Apr; 70(4):526-39. PMID: 19358790.
        View in: PubMed
      43. Feifel D, Mexal S, Melendez G, Liu PY, Goldenberg JR, Shilling PD. The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog. Neuropsychopharmacology. 2009 Jul; 34(8):2011-8. PMID: 19322170.
        View in: PubMed
      44. Feifel D. The use of placebo-controlled clinical trials for the approval of psychiatric drugs: part I-statistics and the case for the "greater good". Psychiatry (Edgmont). 2009 Mar; 6(3):41-3. PMID: 19724754.
        View in: PubMed
      45. Shilling PD, Feifel D. The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle. Pharmacol Biochem Behav. 2008 Oct; 90(4):748-52. PMID: 18577396.
        View in: PubMed
      46. Feifel D. Commentary: why diagnose and treat ADHD in adults? Postgrad Med. 2008 Sep; 120(3):13-5. PMID: 18824821.
        View in: PubMed
      47. Feifel D, MacDonald K. Attention-deficit/hyperactivity disorder in adults: recognition and diagnosis of this often-overlooked condition. Postgrad Med. 2008 Sep; 120(3):39-47. PMID: 18824824.
        View in: PubMed
      48. Feifel D. Transforming the psychiatric inpatient unit from short-term pseudo-asylum care to state-of-the-art treatment setting. Psychiatry (Edgmont). 2008 Sep; 5(9):47-50. PMID: 19727261.
        View in: PubMed
      49. Feifel D, Minassian A, Perry W. Prepulse inhibition of startle in adults with ADHD. J Psychiatr Res. 2009 Jan; 43(4):484-9. PMID: 18674783.
        View in: PubMed
      50. Feifel D, Melendez G, Murray RJ, Tina Tran DN, Rullan MA, Shilling PD. The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacology (Berl). 2008 Oct; 200(2):197-203. PMID: 18568338.
        View in: PubMed
      51. Camacho A, Ng B, Galangue B, Feifel D. Use of risperidone long-acting injectable in a rural border community clinic in southern california. Psychiatry (Edgmont). 2008 Jun; 5(6):43-9. PMID: 19727284.
        View in: PubMed
      52. Feifel D. More depressing news on antidepressants: should we panic? Psychiatry (Edgmont). 2008 Apr; 5(4):35-6. PMID: 19727307.
        View in: PubMed
      53. Cascade EF, Kalali AH, Feifel D. Treatment of autistic children. Psychiatry (Edgmont). 2008 Feb; 5(2):35-7. PMID: 19727292.
        View in: PubMed
      54. Feifel D. ADHD in adults: the invisible rhinoceros. Psychiatry (Edgmont). 2007 Dec; 4(12):60-2. PMID: 20436766.
        View in: PubMed
      55. Cascade EF, Kalali AH, Feifel D. Daytrana: the first year. Psychiatry (Edgmont). 2007 Oct; 4(10):16-7. PMID: 20428306.
        View in: PubMed
      56. Feifel D. An atomoxetine tutorial. Psychiatry (Edgmont). 2007 Aug; 4(8):35-8. PMID: 20532025.
        View in: PubMed
      57. Feifel D. Dosing of divalproex extended release. J Clin Psychiatry. 2007 Jul; 68(7):1146-7; author reply 1147. PMID: 17685756.
        View in: PubMed
      58. Feifel D, Melendez G, Priebe K, Shilling PD. The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res. 2007 Aug 6; 181(2):278-86. PMID: 17559953.
        View in: PubMed
      59. Feifel D, Priebe K. The effects of cross-fostering on inherent sensorimotor gating deficits exhibited by Brattleboro rats. J Gen Psychol. 2007 Apr; 134(2):173-82. PMID: 17503693.
        View in: PubMed
      60. Cascade EF, Kalali AH, Feifel D. Strattera: ups, downs, and emerging uses. Psychiatry (Edgmont). 2007 Apr; 4(4):23-5. PMID: 20711324.
        View in: PubMed
      61. Feifel D. Time to feel good: the therapeutic time course of antidepressants. Psychiatry (Edgmont). 2007 Mar; 4(3):25-7. PMID: 20805906.
        View in: PubMed
      62. Feifel D. When common clinical practice meets evidence-based medicine. Psychiatry (Edgmont). 2006 Dec; 3(12):36-8. PMID: 20877554.
        View in: PubMed
      63. Minassian A, Feifel D, Perry W. The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients. Schizophr Res. 2007 Jan; 89(1-3):225-31. PMID: 17005374.
        View in: PubMed
      64. Cascade EF, Kalali AH, Penn JV, Feifel D. Recent changes in prescriptions for antipsychotics in children and adolescents. Psychiatry (Edgmont). 2006 Sep; 3(9):18-20. PMID: 20975824.
        View in: PubMed
      65. Shilling PD, Kinkead B, Murray T, Melendez G, Nemeroff CB, Feifel D. Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Biol Psychiatry. 2006 Dec 1; 60(11):1278-81. PMID: 16814260.
        View in: PubMed
      66. Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006 Apr; 67(4):554-66. PMID: 16669720.
        View in: PubMed
      67. Miller BP, Perry W, Moutier CY, Robinson SK, Feifel D. Rapid oral loading of extended release divalproex in patients with acute mania. Gen Hosp Psychiatry. 2005 May-Jun; 27(3):218-21. PMID: 15882770.
        View in: PubMed
      68. Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004 Nov; 43(11):1406-14. PMID: 15502600.
        View in: PubMed
      69. Feifel D, Farber RH, Clementz BA, Perry W, Anllo-Vento L. Inhibitory deficits in ocular motor behavior in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004 Sep 1; 56(5):333-9. PMID: 15336515.
        View in: PubMed
      70. Perry W, Minassian A, Feifel D. Prepulse inhibition in patients with non-psychotic major depressive disorder. J Affect Disord. 2004 Aug; 81(2):179-84. PMID: 15306146.
        View in: PubMed
      71. Feifel D, Melendez G, Shilling PD. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology. 2004 Apr; 29(4):731-8. PMID: 14760394.
        View in: PubMed
      72. Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, Gharabawi GM. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry. 2004 Mar; 65(3):386-94. PMID: 15096079.
        View in: PubMed
      73. Feifel D, Shilling PD, Kuczenski R, Segal DS. Altered extracellular dopamine concentration in the brains of cholecystokinin-A receptor deficient rats. Neurosci Lett. 2003 Sep 18; 348(3):147-50. PMID: 12932815.
        View in: PubMed
      74. Feifel D, Melendez G, Shilling PD. A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology. 2003 Apr; 28(4):651-3. PMID: 12655309.
        View in: PubMed
      75. Perry W, Feifel D, Minassian A, Bhattacharjie I, Braff DL. Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry. 2002 Aug; 159(8):1375-81. PMID: 12153831.
        View in: PubMed
      76. Feifel D, Priebe K, Johnstone-Miller E, Morgan CJ. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning. Psychopharmacology (Berl). 2002 Jul; 162(2):138-46. PMID: 12110991.
        View in: PubMed
      77. Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2002 Feb; 63(2):169. PMID: 11874225.
        View in: PubMed
      78. Feifel D, Priebe K, Shilling PD. Startle and sensorimotor gating in rats lacking CCK-A receptors. Neuropsychopharmacology. 2001 Jun; 24(6):663-70. PMID: 11331146.
        View in: PubMed
      79. Feifel D. Rationale and guidelines for the inpatient treatment of acute psychosis. J Clin Psychiatry. 2000; 61 Suppl 14:27-32. PMID: 11154014.
        View in: PubMed
      80. Feifel D, Reza TL. Effects of neurotensin administered into the ventral tegmental area on prepulse inhibition of startle. Behav Brain Res. 1999 Dec; 106(1-2):189-93. PMID: 10595435.
        View in: PubMed
      81. Feifel D. Individual differences in prepulse inhibition of startle as a measure of individual dopamine function. Behav Neurosci. 1999 Oct; 113(5):1020-9. PMID: 10571484.
        View in: PubMed
      82. Feifel D, Moutier CY, Swerdlow NR. Attitudes toward psychiatry as a prospective career among students entering medical school. Am J Psychiatry. 1999 Sep; 156(9):1397-402. PMID: 10484951.
        View in: PubMed
      83. Feifel D, Priebe K. The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating. Psychopharmacology (Berl). 1999 Sep; 146(2):175-9. PMID: 10525752.
        View in: PubMed
      84. Feifel D, Reza TL, Wustrow DJ, Davis MD. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther. 1999 Feb; 288(2):710-3. PMID: 9918579.
        View in: PubMed
      85. Feifel D, Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berl). 1999 Jan; 141(1):93-8. PMID: 9952070.
        View in: PubMed
      86. Feifel D, Swerdlow NR. The modulation of sensorimotor gating deficits by mesolimbic cholecystokinin. Neurosci Lett. 1997 Jun 20; 229(1):5-8. PMID: 9224788.
        View in: PubMed
      87. Feifel D, Minor KL, Dulawa S, Swerdlow NR. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res. 1997 Jun 20; 760(1-2):80-4. PMID: 9237521.
        View in: PubMed
      88. Feifel D, Reza TL, Robeck SL. Pro-dopamine effects of neurotensin on sensorimotor gating deficits. Peptides. 1997; 18(9):1457-60. PMID: 9392852.
        View in: PubMed
      89. Feifel D. Attention-deficit hyperactivity disorder in adults. Postgrad Med. 1996 Sep; 100(3):207-11, 215-8. PMID: 8795655.
        View in: PubMed
      David's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _
      Back to TOP